Enzychem Lifesciences Corporation
Enzychem Lifesciences Corporation operates in Diversified Metals & Mining.
Enzychem Lifesciences Corporation (183490) - Total Liabilities
Latest total liabilities as of June 2024: ₩13.44 Billion KRW
Based on the latest financial reports, Enzychem Lifesciences Corporation (183490) has total liabilities worth ₩13.44 Billion KRW as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Enzychem Lifesciences Corporation - Total Liabilities Trend (2016–2023)
This chart illustrates how Enzychem Lifesciences Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Enzychem Lifesciences Corporation Competitors by Total Liabilities
The table below lists competitors of Enzychem Lifesciences Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
LUNDIN PETROL - Dusseldorf Stock Exchang
DU:LYV
|
Germany | €95.20 Million |
|
NWS HLDGS
BE:NWS
|
Germany | €111.73 Billion |
|
MagForce AG
PINK:MGFRF
|
USA | $35.99 Million |
|
RepliCel Life Sciences Inc
PINK:REPCF
|
USA | $1.22 Million |
|
CPU Softwarehouse AG
F:CPU2
|
Germany | €741.23K |
Liability Composition Analysis (2016–2023)
This chart breaks down Enzychem Lifesciences Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Enzychem Lifesciences Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Enzychem Lifesciences Corporation (2016–2023)
The table below shows the annual total liabilities of Enzychem Lifesciences Corporation from 2016 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | ₩16.92 Billion | -63.07% |
| 2022-12-31 | ₩45.81 Billion | -21.59% |
| 2021-12-31 | ₩58.42 Billion | +13.84% |
| 2020-12-31 | ₩51.32 Billion | +368.65% |
| 2019-12-31 | ₩10.95 Billion | +33.08% |
| 2018-12-31 | ₩8.23 Billion | -32.78% |
| 2017-12-31 | ₩12.24 Billion | +26.05% |
| 2016-12-31 | ₩9.71 Billion | -- |